Iontotherapeutic device and process and iontotherapeutic unit dose

• US 5,042,975 A
• Filed: 05/07/1987
• Issued: 08/27/1991
• Est. Priority Date: 07/25/1986
• Status: Expired due to Fees

• Current Assignee: Rutgers University
• Original Assignee: Rutgers University
• Inventors: Sun, Ying, Liu, Jue-Chen, Siddiqui, Ovais, Kong-Jiann Li, John, Chien, Yie W., Shi, Wei-Min
• Primary Examiner(s): Cohen, Lee S.
• Application Number:
  US07/046,984
• Time in Patent Office: 1,573 Days
• Field of Search: 604/20, 604/50, 128/802, 128/803, 128/798, 128/423 R
• US Class Current: 604/20
• CPC Class Codes: A61N 1/044 Shape of the electrode
• CPC Class Codes: A61N 1/0448 Drug reservoir
• CPC Class Codes: A61N 1/303 Constructional details electrodes for external use A61N1/0428

Abstract

This invention relates to development of an iontotherapeutic device for regulated transdermal systemic administration of ionizable pharmaceutical compounds.

It also provides an iontotherapeutic process for transdermal administration of ionized pharmaceuticals, particularly those which are otherwise transdermally absorbed to a small degree or not all, such as peptide pharmaceuticals, for example, insulins. The invention also relates to unit dose forms, for example, those in which an ionized pharmaceutical is dispersed in a hydrophilic polymer. The unit dose is adapted to be assembled as part of the pharmaceutical reservoir electrode, so that the ionized pharmaceutical will be delivered transdermally and then be absorbed systemically when the iontotherapeutic device is in operation.

Claims

1. A transdermal periodic iontotherapeutic process for administering a controlled and systemically effective amount of a pharmaceutically stable and transdermally absorbable peptide pharmaceutical, by

(1) assembling a dosage unit containing a pharmaceutically acceptable aqueous solution of said peptide into a receptacle of a reservoir electrode of a transdermal periodic iontotherapeutic system, which electrode is a cathode or anode depending upon whether said peptide is anionic or cationic, said solution having a pH at least about 1.0 pH unit below or above the isoelectric point of said peptide;

(2) placing the cathode and anode electrodes of said transdermal periodic iontotherapeutic system in electrical contact with the intact skin to be treated; and

(3) applying to said electrodes an iontotherapeutically effective, periodic DC current of up to about 10 mA based on a reservoir electrode/skin-contacting area of about 5 cm, which DC periodic current is monitored and adjusted as required to maintain a constant current intensity within predetermined minimum and maximum levels, using

(a) a periodic waveform in the square, triangular, sinusoidal, trapezoidal, or other acceptable geometric form, or combinations thereof,

(b) a physiologically acceptable repetition frequency of at least about 10 Hz, and

(c) an on/off ratio of from 1/50 to 10/1;

said process providing a systemically effective absorption of said peptide pharmaceutical from said solution at a rate of at least 500 percent from that provided by passive diffusion transdermal absorption from said solution during an administration time of at least 2 hours.

2. A process of claim 1 in which the pH of the peptide solution is at least about 1.5 pH units below or above the isoelectric point of said peptide.

3. A process of claim 1 in which the pH of the peptide solution is at least about 2.0 pH units below or above the isoelectric point of said peptide.

4. A process of claim 1 in which the pH of the peptide solution is about 1.5 or about 2.0 pH units below the isoelectric point of the peptide.

5. A process of claim 1 in which the peptide is insulin and the pH of the insulin solution is in the range of about pH 3.0 to pH 4.0.

6. A process of claim 5 in which the pH of the insulin solution is about pH 3.6.

7. A process of claim 1 in which the current intensity is not more than about 5 mA based on a reservoir electrode skin-contacting area of about 5 cm².

8. A process of claim 1 in which the current intensity is not more than about 2 mA based on a reservoir electrode skin-contacting area of about 5 cm².

9. A process of claim 1 in which the current intensity is not more than 1 mA based on a reservoir electrode/skincontacting area of about 5 cm².

10. A process of claim 1 in which the periodic DC current has a square waveform.

11. A process of claim 1 in which the periodic DC current has a triangular waveform.

12. A process of claim 1 in which the periodic DC current has a sinusoisal waveform.

13. A process of claim 1 in which the periodic DC current has a trapezoidal waveform.

14. A process of claim 1 in which the peptide has at least 5 amino acid units.

15. A process of claim 1 in which the peptide has at least 9 amino acid units.

16. A process of claim 15 in which the peptide has 9 amino acid units.

17. A process of claim 16 in which the peptide is vasopressin.

18. A process of claim 1 in which the periodic DC current has an administration time of less than about 1 hr followed by multiple repeats of said periodic DC current administration, said periodic DC current administrations being spaced by intervals which are at least as long as the periodic DC current administration times.

19. A process of claim 18 wherein the solution is an insulin solution having a pH which is at least about 1.5 pH units lower or higher than the isoelectric point of the insulin, the current intensity not more than about 2 mA based on a reservoir electrode skin-contacting surface area of about 5 cm², the administration times are not more than about 40 minutes, and the repetition frequency is at least about 1000 Hz.

20. A process of claim 19 in which the periodic waveform is in the square form.

21. A process of claim 19 in which the periodic waveform is in the triangular form.

22. A process of claim 19 in which the periodic waveform is in the sinusoidal form.

23. A process of claim 19 in which the periodic waveform is in the trapezoidal form.

24. A process of claim 1 in which the solution is an insulin solution having a pH which is at least about 1.5 pH units lower or higher than the isoelectric point of the insulin, said insulin transdermally administered at a rate having a skin permeability coefficient of at least 35×

10^-7 cm/hr as measured in the Valia-Chien cell using a current intensity of 1 mA, on/off ratio of 1/1, and a repetition frequency of 2000 Hz.

25. A process of claim 24 in which pH is at least about 1.5 pH units lower than the isoelectric point of insulin.

26. A process of claim 24 in which the pH is about 3.6.

27. A process of claim 1 in which the ionic strength of said solution does not exceed about 0.5.

28. A process of claim 27 in which an ionic strength of said solution does not exceed about 0.3.

29. A process of claim 27 in which the peptide pharmaceutical is an insulin or vasopressin.

30. A sterile unit dose adapted to be removably inserted into the receptacle of a reservoir electrode of a transdermal periodic iontotherapeutic system, said unit dose to be used in electrical contact with intact skin to be iontotherapeutically treated to administer transdermally a systemically effective dose amount of a pharmaceutically effective and transdermally absorbable peptide;

said unit dose containing a sterile solution of said peptide having an iontotherapeutically effective and physiologically acceptable pH at least about one pH unit lower or higher than the isoelectric point of said peptide so as to provide said pharmaceutical in ionized form;

said solution having low ionic strength;

said unit dose adapted to permit said peptide to be released upon application to the reservoir electrode of a periodic DC current using a selected waveform in an iontotherapeutic process.

31. A unit dose of claim 30 in which the pH of the peptide solution is at least about 1.5 pH units above or below the isoelectric point of the peptide.

32. A unit dose of claim 31 in which the peptide is contained and uniformly dispersed in a polymeric matrix disc in which the polymer used in making the matrix disc is essentially non-ionic, hydrophilic and essentially compatible with said peptide and the intact skin to be treated.

33. A unit dose of claim 32 in which the polymer is a cellulose-type polymer.

34. A unit dose of claim 31 in which the peptide is insulin.

35. A unit dose of claim 34 in which the pH is in the range of 3.0 to 4.0

36. A unit dose of claim 34 in which the pH is about 3.6.

37. A unit dose of claim 31 in which the peptide is insulin and the pH is about 3.6.

38. A unit dose of claim 30 in which the peptide is vasopressin.

39. A transdermal periodic iontotherapeutic device for transdermally administering a systemically effective amount of an ionized peptide pharmaceutical comprising

(1) a DC power supply capable of providing an iontotherapeutically effective and physiologically acceptable DC current in the range up to about 10 mA;

(2) a periodic waveform generator electrically connected to the DC power supply and having integrated circuitry capable of providing (1) a periodic waveform in the square, triangular, sinusoidal, trapezoidal, or other acceptable geometric form or combination thereof;

(2) an on/off ratio of 1/50 to 10/1; and

a repetition frequency from about 10 Hz to about 50 KHz;

(3) an output circuit electrically connected to said waveform generator which (1) can provide a periodic DC current in a pre-selected waveform of said forms;

(b) monitors current intensity delivered;

(c) adjusts and maintains the current intensity within predetermined maximum and minimum levels and (d) delivers the current to a reservoir electrode for iontotherapeutic transdermal administration of said peptide pharmaceutical;

(4) a pharmaceutical reservoir electrode which can be preselected to be either the cathode or the anode depending upon whether the ionized pharmaceutical is anionic or cationic;

said electrode having a receptacle adapted to receive a unit dose of said peptide pharmaceutical in which said peptide is in aqueous solution at a pH at least 1.0 pH unit below or above the isoelectric point of said peptide;

said electrode with said received unit dose adapted to be placed in electrical contact with the intact skin to be treated iontotherapeutically;

said electrode having a terminal to receive for transmission through said unit dose the said periodic DC current and said unit dose adapted to be in electrical contact with said terminal; and

(5) receptor electrode adapted to be in electrical contact with the intact skin to be treated and forming with said pharmaceutical reservoir electrode a combination of anode and cathode electrodes;

said electrodes electrically connected to said output circuit and providing when placed upon the skin of a subject being treated a current path through the intervening tissue of the subject being treated.

40. A device of claim 39 in which the DC current is generated in the periodic square waveform by said generator and is transmitted by said output circuit to said electrodes to effect iontotherapy.

41. A device of claim 39 in which the DC current is generated in the periodic triangular waveform by said generator and is transmitted by said output circuit to said electrodes to effect iontotherapy.

42. A device of claim 39 in which the DC current is generated in the periodic sinusoidal waveform by said generator and is transmitted by said output circuit to said electrodes to effect iontotherapy.

43. A device of claim 39 in which the DC current is generated in the periodic trapezoidal waveform by said generator and is transmitted by said output circuit to said electrodes to effect iontotherapy.

44. A device of claim 39 which is portable in size.

45. A device of claim 39 which is portable in size and has means for attachment to the subject being treated iontotherapeutically.

46. A device of claim 39 in which the output circuit is multi-channeled.

47. A device of claim 46 which has multiple pairs of electrodes electrically connected to said output circuit and can be applied to multiple number of subjects being treated iontotherapeutically.